Cargando…

Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients

Background: Although useful in the time-race against COVID-19, CPAP cannot provide oxygen over the physiological limits imposed by severe pulmonary impairments. In previous studies, we reported that the administration of the SLAB51 probiotics reduced risk of developing respiratory failure in severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinchieri, Vito, Marazzato, Massimiliano, Ceccarelli, Giancarlo, Lombardi, Francesca, Piccirilli, Alessandra, Santinelli, Letizia, Maddaloni, Luca, Vassalini, Paolo, Mastroianni, Claudio Maria, d’Ettorre, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405060/
https://www.ncbi.nlm.nih.gov/pubmed/36009399
http://dx.doi.org/10.3390/biomedicines10081851
_version_ 1784773787539996672
author Trinchieri, Vito
Marazzato, Massimiliano
Ceccarelli, Giancarlo
Lombardi, Francesca
Piccirilli, Alessandra
Santinelli, Letizia
Maddaloni, Luca
Vassalini, Paolo
Mastroianni, Claudio Maria
d’Ettorre, Gabriella
author_facet Trinchieri, Vito
Marazzato, Massimiliano
Ceccarelli, Giancarlo
Lombardi, Francesca
Piccirilli, Alessandra
Santinelli, Letizia
Maddaloni, Luca
Vassalini, Paolo
Mastroianni, Claudio Maria
d’Ettorre, Gabriella
author_sort Trinchieri, Vito
collection PubMed
description Background: Although useful in the time-race against COVID-19, CPAP cannot provide oxygen over the physiological limits imposed by severe pulmonary impairments. In previous studies, we reported that the administration of the SLAB51 probiotics reduced risk of developing respiratory failure in severe COVID-19 patients through the activation of oxygen sparing mechanisms providing additional oxygen to organs critical for survival. Methods: This “real life” study is a retrospective analysis of SARS-CoV-2 infected patients with hypoxaemic acute respiratory failure secondary to COVID-19 pneumonia undergoing CPAP treatment. A group of patients managed with ad interim routinely used therapy (RUT) were compared to a second group treated with RUT associated with SLAB51 oral bacteriotherapy (OB). Results: At baseline, patients receiving SLAB51 showed significantly lower blood oxygenation than controls. An opposite condition was observed after 3 days of treatment, despite the significantly reduced amount of oxygen received by patients taking SLAB51. At 7 days, a lower prevalence of COVID-19 patients needing CPAP in the group taking probiotics was observed. The administration of SLAB51 is a complementary approach for ameliorating oxygenation conditions at the systemic level. Conclusion: This study proves that probiotic administration results in an additional boost in alleviating hypoxic conditions, permitting to limit on the use of CPAP and its contraindications.
format Online
Article
Text
id pubmed-9405060
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94050602022-08-26 Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients Trinchieri, Vito Marazzato, Massimiliano Ceccarelli, Giancarlo Lombardi, Francesca Piccirilli, Alessandra Santinelli, Letizia Maddaloni, Luca Vassalini, Paolo Mastroianni, Claudio Maria d’Ettorre, Gabriella Biomedicines Article Background: Although useful in the time-race against COVID-19, CPAP cannot provide oxygen over the physiological limits imposed by severe pulmonary impairments. In previous studies, we reported that the administration of the SLAB51 probiotics reduced risk of developing respiratory failure in severe COVID-19 patients through the activation of oxygen sparing mechanisms providing additional oxygen to organs critical for survival. Methods: This “real life” study is a retrospective analysis of SARS-CoV-2 infected patients with hypoxaemic acute respiratory failure secondary to COVID-19 pneumonia undergoing CPAP treatment. A group of patients managed with ad interim routinely used therapy (RUT) were compared to a second group treated with RUT associated with SLAB51 oral bacteriotherapy (OB). Results: At baseline, patients receiving SLAB51 showed significantly lower blood oxygenation than controls. An opposite condition was observed after 3 days of treatment, despite the significantly reduced amount of oxygen received by patients taking SLAB51. At 7 days, a lower prevalence of COVID-19 patients needing CPAP in the group taking probiotics was observed. The administration of SLAB51 is a complementary approach for ameliorating oxygenation conditions at the systemic level. Conclusion: This study proves that probiotic administration results in an additional boost in alleviating hypoxic conditions, permitting to limit on the use of CPAP and its contraindications. MDPI 2022-08-01 /pmc/articles/PMC9405060/ /pubmed/36009399 http://dx.doi.org/10.3390/biomedicines10081851 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Trinchieri, Vito
Marazzato, Massimiliano
Ceccarelli, Giancarlo
Lombardi, Francesca
Piccirilli, Alessandra
Santinelli, Letizia
Maddaloni, Luca
Vassalini, Paolo
Mastroianni, Claudio Maria
d’Ettorre, Gabriella
Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients
title Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients
title_full Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients
title_fullStr Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients
title_full_unstemmed Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients
title_short Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients
title_sort exploiting bacteria for improving hypoxemia of covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405060/
https://www.ncbi.nlm.nih.gov/pubmed/36009399
http://dx.doi.org/10.3390/biomedicines10081851
work_keys_str_mv AT trinchierivito exploitingbacteriaforimprovinghypoxemiaofcovid19patients
AT marazzatomassimiliano exploitingbacteriaforimprovinghypoxemiaofcovid19patients
AT ceccarelligiancarlo exploitingbacteriaforimprovinghypoxemiaofcovid19patients
AT lombardifrancesca exploitingbacteriaforimprovinghypoxemiaofcovid19patients
AT piccirillialessandra exploitingbacteriaforimprovinghypoxemiaofcovid19patients
AT santinelliletizia exploitingbacteriaforimprovinghypoxemiaofcovid19patients
AT maddaloniluca exploitingbacteriaforimprovinghypoxemiaofcovid19patients
AT vassalinipaolo exploitingbacteriaforimprovinghypoxemiaofcovid19patients
AT mastroianniclaudiomaria exploitingbacteriaforimprovinghypoxemiaofcovid19patients
AT dettorregabriella exploitingbacteriaforimprovinghypoxemiaofcovid19patients